Enalapril Maleate Tablets Recalled Due to Manufacturing Practice Deviations
Golden State Medical Supply Inc. is recalling Enalapril Maleate Tablets due to manufacturing practice deviations. The voluntary recall involves 9,058 units distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall initiated voluntarily by the firm for manufacturing practice deviations. No illnesses or injuries have been reported, and the hazard is theoretical rather than a confirmed product defect, meeting the rubric criterion for voluntary precautionary recalls.
Plain-English summary
Enalapril Maleate Tablets, USP, 5 mg, packaged in bottles of 90 tablets, are being recalled by Golden State Medical Supply Inc. in a voluntary, firm-initiated recall. The recall involves 9,058 units manufactured by Taro Pharmaceutical Industries, Ltd., and packaged by Golden State Medical Supply, Inc., based in Camarillo, California.
The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations. As of the report date of July 13, 2022, no illnesses or injuries have been reported in connection with this product.
The affected product was distributed nationwide to pharmacies and consumers in Pennsylvania, Massachusetts, Ohio, Texas, Illinois, North Dakota, and Hawaii. Multiple lot numbers are affected with varying expiration dates through March 2024.
Consumers who have this medication should check the lot number against the FDA's recall list (D-1178-2022). Those with affected batches should contact their pharmacy or healthcare provider for guidance on whether to continue use or obtain a replacement from an unaffected lot.
The recalled product
- Product
- ENALAPRIL MALEATE (ENALAPRIL MALEATE)
- Brand
- ENALAPRIL MALEATE
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Antihypertensive
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: GS029041
- GS029353
- GS02986
- 5 mg
- 90 tablets
- Exp.: 09/2022
- Lot: GS030056
- GS030869
- GS033943
- Exp.: 10/2022
- Lots: GS034490
- GS035197
- Exp.:02/2023
- Lots: GS035198
- Exp.: 03/2023
- Lots: GS035596
- GS035947
- GS036759
- GS037400
- Exp.: 06/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ENALAPRIL MALEATE
- ModerateEnalapril Maleate 20 mg tablets recalled for out-of-specification impurities
FDA (Drugs) · 2026-05-13
- ModeratePrescription drug Enalapril Maleate recalled for manufacturing deviations
FDA (Drugs) · 2022-07-13
- ModeratePrescription Drug Recall: Enalapril Maleate Due to Manufacturing Deviations
FDA (Drugs) · 2022-07-13
- ModerateFDA Recalls Enalapril Maleate Tablets Over Manufacturing Practice Deviations
FDA (Drugs) · 2022-07-13
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27